Journals / Anadolu Kardiyoloji Dergisi / 2009 / Cilt: 9 - Sayı: 5

Kardiyak sendrom X'li hastalarda nebivolol tedavisi ile endotel fonksiyonu ve egzersiz toleransı düzelmektedir

Nebivolol therapy improves endothelial function and increases exercise tolerance in patients with cardiac syndrome X

Pages
371–379
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: At baseline, plasma level of NOx, L-arginine, and L-arginine/ADMA ratio were lower (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Ob­jec­ti­ve: We sought to determine whether nebivolol affects coronary endothelial function and exercise induced ischemia in patients with cardiac syndrome X (CSX).
📊
Key Findings & Data:After a 2-week washout period, 38 patients with cardiac syndrome X were randomized to receive either nebivolol 5 mg daily (n=19) or metoprolol 50 mg daily (n=19) in a single- blind design for 12 weeks.
💡
Conclusion & Impact:Results: At baseline, plasma level of NOx, L-arginine, and L-arginine/ADMA ratio were lower (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Ob­jec­ti­ve: We sought to determine whether nebivolol affects coronary endothelial function and exercise induced ischemia in patients with cardiac syndrome X (CSX). Methods: The study protocol undertaken was based on a single-blind randomized controlled prospective study. After a 2-week washout period, 38 patients with cardiac syndrome X were randomized to receive either nebivolol 5 mg daily (n=19) or metoprolol 50 mg daily (n=19) in a single- blind design for 12 weeks. The control group under study was consisted of 16 age- and gender-matched subjects with negative treadmill exercise tests. Plasma endothelial nitric oxide (NOx), L-arginine, and asymmetric dimethylarginine (ADMA) were measured in all patients at baseline and after 12 weeks of treatment. Statistical differences among groups were tested by one-way analysis of variance and unpaired samples t test for parametric; Kruskal-Wallis and Mann-Whitney U tests for non-parametric variables, respectively. A paired – samples t test was used to compare continuous variables before and after drug therapy. Results: At baseline, plasma level of NOx, L-arginine, and L-arginine/ADMA ratio were lower (p

Özet

Amaç: Çalışmamızda, kardiyak sendrom X’li (KSX) hastalarda nebivolol tedavisinin endotel fonksiyonu ve egzersizin indüklediği iskemi üzerine etkisini araştırdık. Yöntemler: Çalışma tek kör, randomize kontrollü ve prospektif olarak dizayn edildi. İki haftalık ilaçsız periyod sonrasında kardiyak sendrom X’li 38 hasta nebivolol 5 mg/gün (n=19) veya metoprolol 50 mg/gün (n=19) gruplarına tek kör olarak randomize edilerek 12 haftalık tedavi sonrası tekrar değerlendirildi. Kontrol grubu olarak efor testi negatif olan yaş ve cinsiyet uyumlu 16 hasta alındı. Tüm hastalarda tedavi öncesi ve 12 haftalık tedavi sonrası plazma endotelyal nitrik oksit (NOx), L-arjinin ve asimetrik dimetilarjinin (ADMA) düzeyleri ölçüldü. Gruplar arası çoklu karşılaştırmalar parametrik değişkenler için tek yönlü ANOVA ve eşleştirilmemiş örneklem t testleri, parametrik olmayan değişkenler için ise Kruskal–Wallis ve Mann Whitney U testleri ile yapıldı. İlaç tedavisi öncesi ve sonrası değişkenlerin karşılaştırılması eşleştirilmiş örneklem t testi ile yapıldı. Bulgular: Kardiyak sendrom X’li hastaları 16 kişiden oluşan sağlıklı kontrol grubu ile karşılaştırıldığında, kontrol grubuna kıyasla KSX’li hastalarda plazma NOx, L-arjinin ve L-arjinin/ADMA düzeyi azalmış, plazma ADMA düzeyi ise artmış olarak bulundu. On iki hafta süren tedavi sonrası metoprolol grubuna kıyasla nebivolol grubunda plazma NOx, L-arjinin ve L-arjinin /ADMA düzeyi artmış, ADMA düzeyi ise azalmış olarak saptandı (p

🔖

Cite This Article

ERBİL, M. K., AKGÜL, E. Ö., ERDAMAR, H., BİLGE, C., ÇAKIR, E., YAZICI, H. U., TAVİL, Y., TURFAN, M., CEMRİ, M., POYRAZ, F., ŞEN, N., OKYAY, K. (2022). Kardiyak sendrom X'li hastalarda nebivolol tedavisi ile endotel fonksiyonu ve egzersiz toleransı düzelmektedir. Anadolu Kardiyoloji Dergisi, Cilt: 9 - Sayı: 5, 371–379. https://ajindex.com/articles/436951

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Kemp HG. Left ventricular function in patients with anginal syndrome and normal coronary arteriograms. Am J Cardiol 1973; 32: 375-6
  2. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-660
  3. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med 1993; 328: 1659-64
  4. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032-7
  5. Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 2002; 90: 974-82
  6. Fragasso G, Chierchia SL, Pizzetti G, Rossetti E, Carlino M, Gerosa S, et al. Impaired left ventricular filling dynamics in patients with angina and angiographically normal coronary arteries: effect of beta adrenergic blockade. Heart 1997; 77: 32-9
  7. Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Verhaegen H, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta-1-adrenergic antagonist. J Cardiovasc Pharmacol 1988; 11: 552- 63
  8. Van Neuten L, Taylor FR, Robertson JL. Nebivolol versus atenolol and placebo in essential hypertension: a double-blind randomized trial. J Hum Hypertens 1998; 12: 135-40
  9. Ignarro LJ, Byrns RE, Trinh K, Sisodia M, Buga GM. Nebivolol: a selective beta (1)adrenergic receptor antagonist relaxes vascular smooth muscle by nitric oxide- and cyclic GMP dependent mechanisms. Nitric Oxide 2002; 7: 75-82
  10. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine / NO dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-71
  11. Dawes M, Brett SE, Chowiencyk PJ, Mant TG, Ritter JM. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999; 48: 460-3
  12. Campeau L. The Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later. Can J Cardiol 2002; 18: 371-9
  13. Miranda, KM, Espey MG, Wink DA. A rapid, simple spectro